These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 30653440)

  • 41. Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials.
    Zaccardi F; Kunutsor SK; Seidu S; Davies MJ; Khunti K
    Atherosclerosis; 2018 Apr; 271():223-231. PubMed ID: 29524865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study.
    Hamoui O; Omar MI; Raal FJ; Rashed W; Kane A; Alami M; Abreu P; Mashhoud W; Alsheikh-Ali AA
    BMC Cardiovasc Disord; 2019 Mar; 19(1):61. PubMed ID: 30876390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management.
    Harrison TN; Hsu JY; Rosenson RS; Levitan EB; Muntner P; Cheetham TC; Wei R; Scott RD; Reynolds K
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):29-36. PubMed ID: 29417422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
    Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
    Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
    Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
    Sharma M; Ansari MT; Abou-Setta AM; Soares-Weiser K; Ooi TC; Sears M; Yazdi F; Tsertsvadze A; Moher D
    Ann Intern Med; 2009 Nov; 151(9):622-30. PubMed ID: 19884623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patients.
    Sudano I; Hess L; Noll G; Arnet D
    Swiss Med Wkly; 2011; 141():w13200. PubMed ID: 21574067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA).
    Klug E; Raal FJ; Marais AD; Smuts CM; Schamroth C; Jankelow D; Blom DJ; Webb DA
    S Afr Med J; 2018 Oct; 108(11b):973-1000. PubMed ID: 30421699
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exploring the Management of Statin Intolerant Patients: 2016 and Beyond.
    Katsiki N; Athyros VG; Karagiannis A
    Curr Vasc Pharmacol; 2016; 14(6):523-533. PubMed ID: 26916398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.
    O'Connor PJ; Gray RJ; Maciosek MV; Fillbrandt KM; DeFor TA; Alexander CM; Weiss TW; Teutsch SM
    Prev Chronic Dis; 2005 Jul; 2(3):A05. PubMed ID: 15963307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
    Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M
    Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?
    Muntean DM; Thompson PD; Catapano AL; Stasiolek M; Fabis J; Muntner P; Serban MC; Banach M
    Drug Discov Today; 2017 Jan; 22(1):85-96. PubMed ID: 27634340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Statin Intolerance From a Clinician's Perspective.
    Whayne TF
    Angiology; 2016 Mar; 67(3):205-7. PubMed ID: 26019266
    [No Abstract]   [Full Text] [Related]  

  • 60. Addressing statin adverse effects in the clinic: the 5 Ms.
    Katz DH; Intwala SS; Stone NJ
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):533-42. PubMed ID: 24770611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.